Australia Red Biotechnology Market Size & Outlook

The red biotechnology market in Australia is expected to reach a projected revenue of US$ 44,891.4 million by 2030. A compound annual growth rate of 15.5% is expected of Australia red biotechnology market from 2024 to 2030.
Revenue, 2023 (US$M)
$16,335.3
Forecast, 2030 (US$M)
$44,891.4
CAGR, 2024 - 2030
15.5%
Report Coverage
Australia

Australia red biotechnology market highlights

  • The Australia red biotechnology market generated a revenue of USD 16,335.3 million in 2023 and is expected to reach USD 44,891.4 million by 2030.
  • The Australia market is expected to grow at a CAGR of 15.5% from 2024 to 2030.
  • In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
  • Gene Therapy Products is the most lucrative product segment registering the fastest growth during the forecast period.


Red biotechnology market data book summary

Market revenue in 2023USD 16,335.3 million
Market revenue in 2030USD 44,891.4 million
Growth rate15.5% (CAGR from 2023 to 2030)
Largest segmentMonoclonal antibodies
Fastest growing segmentGene Therapy Products
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationMonoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products, Gene Therapy Products, Cell Therapy Products, Tissue-Engineered Products, Stem Cells, Cell Culture, Viral Vector, Enzymes, Kits and Reagents, Animal Models, Molecular Diagnostics
Key market players worldwideMerck KGaA, Roche Holding AG ADR, Pfizer Inc, Regeneron Pharmaceuticals Inc, AstraZeneca PLC, Gilead Sciences Inc, Biogen Inc, Amgen Inc, Bristol-Myers Squibb Co, Takeda Pharmaceutical Co Ltd


Other key industry trends

  • In terms of revenue, Australia accounted for 3.3% of the global red biotechnology market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, Japan red biotechnology market is projected to lead the regional market in terms of revenue in 2030.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 54,951.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Red Biotechnology Market Companies

Name Profile # Employees HQ Website

Australia red biotechnology market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to red biotechnology market will help companies and investors design strategic landscapes.


Monoclonal antibodies was the largest segment with a revenue share of 49.72% in 2023. Horizon Databook has segmented the Australia red biotechnology market based on monoclonal antibodies, polyclonal antibodies, recombinant proteins, vaccines, cell-based immunotherapy products, gene therapy products, cell therapy products, tissue-engineered products, stem cells, cell culture, viral vector, enzymes, kits and reagents, animal models, molecular diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Australia red biotechnology market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Australia red biotechnology market databook

  • Our clientele includes a mix of red biotechnology market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Australia red biotechnology market , including forecasts for subscribers. This country databook contains high-level insights into Australia red biotechnology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Australia red biotechnology market outlook size, by product, 2018-2030 (US$M)

Australia Red Biotechnology Market Outlook Share, 2023 & 2030 (US$M)

Australia red biotechnology market outlook size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more